Theratechnologies (THTX) to Release Quarterly Earnings on Tuesday

Theratechnologies (NASDAQ:THTX) will announce its earnings results before the market opens on Tuesday, September 26th.

Theratechnologies (NASDAQ:THTX) last announced its earnings results on Wednesday, July 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.16). The firm had revenue of $17.55 million during the quarter. On average, analysts expect Theratechnologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theratechnologies Stock Performance

Shares of THTX opened at $2.21 on Tuesday. Theratechnologies has a 1-year low of $0.90 and a 1-year high of $11.06. The stock has a market capitalization of $53.48 million, a P/E ratio of -1.45 and a beta of 1.25. The business’s 50-day moving average price is $2.01 and its 200 day moving average price is $3.04.

Institutional Investors Weigh In On Theratechnologies

Institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. lifted its position in shares of Theratechnologies by 2.3% in the second quarter. Osaic Holdings Inc. now owns 444,155 shares of the company’s stock worth $374,000 after purchasing an additional 10,000 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of Theratechnologies during the 1st quarter valued at $66,000. Soleus Capital Management L.P. increased its stake in shares of Theratechnologies by 9.9% in the fourth quarter. Soleus Capital Management L.P. now owns 8,799,125 shares of the company’s stock worth $7,768,000 after acquiring an additional 791,411 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Theratechnologies by 658.0% during the fourth quarter. Millennium Management LLC now owns 80,868 shares of the company’s stock worth $73,000 after acquiring an additional 70,200 shares in the last quarter. Finally, Morgan Stanley boosted its position in Theratechnologies by 3.2% during the fourth quarter. Morgan Stanley now owns 7,877,403 shares of the company’s stock valued at $6,954,000 after purchasing an additional 244,096 shares during the last quarter.

Analysts Set New Price Targets

Separately, National Bank Financial upped their price target on shares of Theratechnologies from C$1.75 to C$7.00 in a research report on Tuesday, August 1st.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients.